by Kyle Doherty
Investigators are examining and implementing several innovations that they hope will combat the persistent issue of limited access to cancer care for patients living in rural areas, including programs aimed at increasing clinical trial enrollment for these … Read more
Clearity’s Perspective: If you or someone you love has been diagnosed with low-grade serous ovarian cancer (LGSOC), consider watching the recording of the OC Education webinar, “But This is Different: Understanding and Getting Support for the Unique Needs of People … Read more
by Lauren Comander
Sophia George, Ph.D., and Matthew Schlumbrecht, M.D., M.P.H., are taking on the world of ovarian cancer research. As researchers for Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, the duo is
… Read moreby Kyle Doherty
A research statement was published by the American Society of Clinical Oncology (ASCO) that describes 4 recommendations for decentralization to improve accessibility of cancer clinical trials.1,2
In the statement, the ASCO panel recommended that the FDA … Read more
by University of Birmingham
A study published in the International Journal of Gynecological Cancer found that the UK’s protocol for picking up early-stage disease in women with high grade serous ovarian cancer—the most common, aggressive, and lethal form of the … Read more
—No difference in adverse events, clinical benefit, OS for patients with or without waivers
by Charles Bankhead
Patients who received protocol waivers in a clinical trial of targeted anticancer therapy had outcomes similar to those who met all enrollment criteria, a large retrospective review showed.
Patients who received waivers had a clinical benefit rate … Read more
As presented at the ESMO Gynaecological Cancers Congress 2024 (Florence, 20–22 June), a post-hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial in patients with high folate receptor alpha (FRalpha), platinum-resistant ovarian cancer revealed that even those who required … Read more
Clearity’s Perspective: This article highlights that some people with ovarian cancer who live in certain geographic locations, like rural areas, may get treated at centers with less experience treating ovarian cancer and/or fewer resources to support whole-person needs. Clearity offers … Read more
by Wayne Kuznar
CHICAGO — Clinical activity and survival outcomes improved with the addition of ipilimumab (Yervoy) to nivolumab (Opdivo) in patients with ovarian or other gynecologic clear cell carcinomas, according to results from the non-comparative phase II BrUOG 354 … Read more
by Silas Inman
The addition of atezolizumab (Tecentriq) to single-agent non–platinum-based chemotherapy and bevacizumab (Avastin) did not provide any additional benefits for patients with recurrent ovarian cancer, according to the final analysis of the phase 3 AGO-OVAR 2.29/ENGOT-ov34 study (NCT03353831) … Read more
by The ASCO Post Staff
Some people with advanced epithelial ovarian cancer may safely avoid having their lymph nodes removed during surgery without it impacting their survival outcomes, helping to reduce the risk of postoperative complications. This research was presented … Read more
Clearity offers emotional support to individuals with ovarian cancer through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team of OC Counselors may be … Read more
by Cynthia McCormick Hibbert
For too many cancer survivors, life after treatment is fraught with a decline in cognitive function known as “chemo brain.”
A newly published study by a Northeastern professor says that yoga might hold the key to … Read more
by Sabrina Serani
The FDA announced new guidance to expand eligibility criteria with the goal of improving participation and diversity in oncology clinical trials.These 3 areas of change include laboratory values, washout periods, and performance status.
While the FDA notes … Read more
— About half of patients responded, duration of response as long as 19 months in three trials
By Charles Bankhead
The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers.
The action represents the first tumor-agnostic approval for an antibody-drug conjugate targeting HER2-positive tumors. According … Read more
A tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues.
Clearity’s Perspective: Most drugs are tested and approved to treat cancers based on where in the body the cancer started and the type of tissue from which it developed. Enhertu (Trastuzumab Deruxtecan, T-Dxd), a HER2-targeted antibody drug conjugate (ADC), already … Read more
Clearity’s Perspective: In the January 17, 2024 update to the National Comprehensive Cancer Network (NCCN) guidelines for ovarian cancer, several new therapies have been added to the list of acceptable regimens for recurrent platinum-resistant ovarian cancer. For example, trastuzumab deruxtecan … Read more
By Erin T. Welsh, MA
Asian, Black and Hispanic women with … Read more
By Ashley Chan
A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.
A phase 3 trial analyzing the treatment combination of avutometinib and defactinib compared with … Read more
In small trial, half had early remission of depressive symptoms after psilocybin-assisted therapy
By Diana Swift
Psilocybin-assisted therapy in a group setting was safe and appeared effective in patients with cancer and depression, according to a small, phase II, open‐label trial.
After one dose of psilocybin among 30 patients, depression severity scores dropped … Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
